These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38402890)

  • 1. Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies.
    Poukka E; Auranen K; Baum U
    Lancet Infect Dis; 2024 May; 24(5):e275. PubMed ID: 38402890
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply.
    Hansen CH; Moustsen-Helms IR; Rasmussen M; Søborg B; Ullum H; Valentiner-Branth P
    Lancet Infect Dis; 2024 May; 24(5):e276. PubMed ID: 38402888
    [No Abstract]   [Full Text] [Related]  

  • 3. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
    Antunes L; Mazagatos C; Martínez-Baz I; Naesens R; Borg ML; Petrović G; Fatukasi T; Jancoriene L; Machado A; Oroszi B; Husa P; Lazar M; Dürrwald R; Howard J; Melo A; Pérez-Gimeno G; Castilla J; Bernaert E; Džiugytė A; Makarić ZL; Fitzgerald M; Mickienė A; Gomez V; Túri G; Součková L; Marin A; Tolksdorf K; Nicolay N; Rose AMC;
    Influenza Other Respir Viruses; 2024 Aug; 18(8):e13360. PubMed ID: 39145535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
    Monge S; Humphreys J; Nicolay N; Braeye T; Van Evercooren I; Holm Hansen C; Emborg HD; Sacco C; Mateo-Urdiales A; Castilla J; Martínez-Baz I; de Gier B; Hahné S; Meijerink H; Kristoffersen AB; Machado A; Soares P; Nardone A; Bacci S; Kissling E; Nunes B;
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13292. PubMed ID: 38654485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The variants of SARS-CoV-2 and the challenges of vaccines.
    Han X; Ye Q
    J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccine breakthrough infections.
    Gupta RK; Topol EJ
    Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.
    Botton J; Semenzato L; Jabagi MJ; Baricault B; Weill A; Dray-Spira R; Zureik M
    JAMA Netw Open; 2022 Mar; 5(3):e220868. PubMed ID: 35234883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic disorders, COVID-19 and vaccine-breakthrough infections.
    Stefan N
    Nat Rev Endocrinol; 2022 Feb; 18(2):75-76. PubMed ID: 34873287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
    Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
    Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: Concerns.
    Daungsupawong H; Wiwanitkit V
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1111. PubMed ID: 38679969
    [No Abstract]   [Full Text] [Related]  

  • 11. Host factors and vaccine efficacy: Implications for COVID-19 vaccines.
    Falahi S; Kenarkoohi A
    J Med Virol; 2022 Apr; 94(4):1330-1335. PubMed ID: 34845730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
    Rashedi R; Samieefar N; Masoumi N; Mohseni S; Rezaei N
    J Med Virol; 2022 Apr; 94(4):1294-1299. PubMed ID: 34796525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoupling of omicron variant infections and severe COVID-19.
    Madhi SA; Ihekweazu C; Rees H; Pollard AJ
    Lancet; 2022 Mar; 399(10329):1047-1048. PubMed ID: 35189080
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccination and COVID-19 Dynamics in Dialysis Patients.
    El Karoui K; Hourmant M; Ayav C; Glowacki F; Couchoud C; Lapidus N;
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):395-402. PubMed ID: 35144970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 vaccine strategies must focus on severe disease and global equity.
    McIntyre PB; Aggarwal R; Jani I; Jawad J; Kochhar S; MacDonald N; Madhi SA; Mohsni E; Mulholland K; Neuzil KM; Nohynek H; Olayinka F; Pitisuttithum P; Pollard AJ; Cravioto A
    Lancet; 2022 Jan; 399(10322):406-410. PubMed ID: 34922639
    [No Abstract]   [Full Text] [Related]  

  • 20. Interim effectiveness of the updated 2023-2024 COVID-19 vaccines in adults with immunocompromizing conditions.
    Pereira MR
    Am J Transplant; 2024 Jun; 24(6):890-891. PubMed ID: 38677653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.